

MIRA INFORM REPORT

Report No. :	530442
Report Date :	22.09.2018

IDENTIFICATION DETAILS

Name :	SHIVA PHARMACHEM SA
Registered Office :	Hauptstrasse 64, 4132 Muttenz/BL
Country :	Switzerland
Financials (as on) :	31.03.2017
Date of Incorporation :	25.08.2014
Com. Reg. No.:	ChE-247-572-776
Legal Form :	Company Limited by Shares
Line of Business :	<ul style="list-style-type: none"> • Other research and experimental development on natural sciences and engineering • Wholesale of chemical products • The company engages in the development, manufacture and distribution of acids, alkyl chlorides and intermediates. The company caters to the needs of industries such as Agrochemicals, Pharmaceutical, Polymers, Fragrance and Cosmetics.
No. of Employees :	1-9

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

MIRA's Rating :

A

Credit Rating	Explanation	Rating Comments
A	Acceptable Risk	Business dealings permissible with moderate risk of default

Status :	Satisfactory
Payment Behaviour :	No Complaints
Litigation :	Clear

NOTES:

Any query related to this report can be made on e-mail: while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating (31.12.2017)	Current Rating (01.04.2018)
Switzerland	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

SWITZERLAND - ECONOMIC OVERVIEW

Switzerland, a country that espouses neutrality, is a prosperous and modern market economy with low unemployment, a highly skilled labor force, and a per capita GDP among the highest in the world. Switzerland's economy benefits from a highly developed service sector, led by financial services, and a manufacturing industry that specializes in high-technology, knowledge-based production. Its economic and political stability, transparent legal system, exceptional infrastructure, efficient capital markets, and low corporate tax rates also make Switzerland one of the world's most competitive economies.

The Swiss have brought their economic practices largely into conformity with the EU's to gain access to the Union's Single Market and enhance the country's international competitiveness. Some trade protectionism remains, however, particularly for its small agricultural sector. The fate of the Swiss economy is tightly linked to that of its neighbors in the euro zone, which purchases half of Swiss exports. The global financial crisis of 2008 and resulting economic downturn in 2009 stalled demand for Swiss exports and put Switzerland into a recession. During this period, the Swiss National Bank (SNB) implemented a zero-interest rate policy to boost the economy, as well as to prevent appreciation of the franc, and Switzerland's economy began to recover in 2010.

The sovereign debt crises unfolding in neighboring euro-zone countries, however, coupled with economic instability in Russia and other Eastern European economies drove up demand for the Swiss franc by investors seeking a safehaven currency. In January 2015, the SNB abandoned the Swiss franc's peg to the euro, roiling global currency markets and making active SNB intervention a necessary hallmark of present-day Swiss monetary policy. The independent SNB has upheld its zero interest rate policy and conducted major market interventions to prevent further appreciation of the Swiss franc, but parliamentarians have urged it to do more to weaken the currency. The franc's strength has made Swiss exports less competitive and weakened the country's growth outlook; GDP growth fell below 2% per year from 2011 through 2017.

In recent years, Switzerland has responded to increasing pressure from neighboring countries and trading partners to reform its banking secrecy laws, by agreeing to conform to OECD regulations on administrative assistance in tax matters, including tax evasion. The Swiss Government has also renegotiated its double taxation agreements with numerous countries, including the US, to incorporate OECD standards.

Source : CIA

COMPANY NAME AND ADDRESS

SHIVA PHARMACHEM SA

Operating address:

Hauptstrasse 64
4132 Muttenz/BL
Switzerland/CH

Telephone: +41 32 9679521

Web site: <http://www.shivapharmachem.com>

E-mail: inquiry@shivapharmachem.eu

WIN Worldbox No.: CH0010346361

VAT-No.: CHE-247.572.776 MWST

UID-No.: CHE247572776

PROFILE

Established: 2014

Line of Business: Pharmaceuticals, Consumer goods wholesale

Industry Division: Services, Wholesale trade

Industry-code (NACE): 7219 Other research and experimental development on natural sciences and engineering

4675 Wholesale of chemical products

Import/Export: Import, Export

Banks: unknown

OPERATIONAL FIGURES

Coverage: Company

Figures: estimated

Financial year: 2018

Employees: 1-9

Sales: USD 10-20 Mio

ACTIVITY

The company engages in the development, manufacture and distribution of acids, alkyl chlorides and intermediates. The company caters to the needs of industries such as Agrochemicals, Pharmaceutical, Polymers, Fragrance and Cosmetics.

Operations and Branches:

At the address, Hauptstrasse 64, 4132 Muttenz, Switzerland, we find office of the company.

REAL ESTATE

Real Estate: The company does not appear to own any property.

COMPANY REGISTER

Company No: ChE-247-572-776
UID-No.: CHE247572776
Legal form: Company limited by shares
Registration: 25.08.2014
Legal status: active
Responsible Register: Handelsregister des Kantons Basel-Landschaft
History: Date of Incorporation Statutes: 19.08.2014

Entry	Deleted	Name
25.08.2014		Shiva Pharmachem SA
25.08.2014		Shiva Pharmachem Ltd (Name translated)
25.08.2014		Shiva Pharmachem AG (Name translated)

Entry	Deleted	Legal domicile
25.08.2014		Muttenz, Switzerland

Entry	Deleted	Address
25.08.2014		Hauptstrasse 64, 4132 Muttenz/BL, Switzerland/CH

Entry	Deleted	Capital
25.08.2014		Share Capital CHF 100,000, paidup CHF 100,000

Entry	Deleted	Capital Structure
25.08.2014		100,000 Registered shares of CHF 1.--

OFFICIAL ADMINISTRATION

Title	Name
President	Agrawal, Vishal Rakesh Citizen: India Residential address: Vadodara / Gujarat, India single signature Registered since: 25.08.2014
Director	Bühlmann, Karl (Charles) Citizen: Rickenbach LU, Switzerland Residential address: La Chaux-de-Fonds, Switzerland single signature Registered since: 25.08.2014

ULTIMATE PARENT COMPANY

Name:	TASH INVESTMENT PRIVATE LIMITED
City/Country:	VADODARA/Gujarat, India/IN

DIRECT OWNER/S

No. of owner/-s:	1
Owner:	The company is foreign owned.
Class:	100%, directly held
Name:	SHIVA PHARMACHEM LIMITED
City/Country:	BARODA/Gujarat, India/IN
Interest:	100,00% voting right, 100,00% capital interest

INVESTMENTS

It is believed that the company has no investments.

FINANCIAL DATA SHIVA PHARMACHEM SA

Consolidation:	unconsolidated	
Industry:	Trade/Industry	
Fiscal year end:	31.03.2017	31.03.2015

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SHIVA PHARMACHEM SA - 530442

PAGE NO. : 7

Number of months:	12	12
Currency:	th. USD	th. USD
Balance Sheet		
Total assets	3,754.3	2,580.5
Capital	108.9	108.0
Other shareholders funds	270.2	48.7
Total shareholders equity	379.1	156.7
Current liabilities	3,375.3	2,423.8
Shareh. equity, min. int. & liabilities	3,754.3	2,580.5
Profit and loss account		
Net sales	13,030.9	1,543.1
Result before taxes	285.7	54.9
Taxes	24.5	6.1
Result before minority interests	261.2	48.7
Result for the financial year	261.2	48.7
Cash flow		
Investments in tangible fixed assets	2.0	

FINANCIAL DATA SHIVA PHARMACHEM LIMITED

Consolidation:	consolidated	
Industry:	Trade/Industry	
Fiscal year end:	31.03.2016	31.03.2015
Number of months:	12	12
Currency:	th. INR	th. INR
Balance Sheet		
Intangible fixed assets	2,538.8	6,797.2
Land and buildings	796,804.0	480,641.4
Other tangible fixed assets	894,415.8	652,324.3
Tangible fixed assets	1,691,219.7	1,132,965.7
Financial fixed assets	16,352.6	105,588.6
other fixed assets	311,205.9	543,690.0
Fixed assets	2,021,317.1	1,789,041.5
Stocks	706,041.0	385,492.2
Trade accounts receivable	1,019,865.8	986,746.0
Cash & Cash Equivalents	421,229.8	196,216.4

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SHIVA PHARMACHEM SA - 530442

PAGE NO. : 8

Securities	0.0	0.0
other trade accounts	342,140.4	344,819.9
Accruals	0.0	0.0
Other current assets	763,370.2	541,036.3
Current assets	2,489,277.0	1,913,274.6
Total assets	4,510,594.1	3,702,316.1
Capital	69,502.0	69,502.0
Other shareholders funds	1,180,889.4	1,062,733.1
Total shareholders equity	1,250,391.4	1,132,235.1
Minority interests	350.7	0.0
long term debt (financial debts)	911,482.6	785,792.5
Provisions	28,698.1	17,294.1
Other non current liabilities	1,790.6	921.1
Non current liabilities	941,971.2	804,007.8
short term debt (financial debts)	1,489,354.3	1,134,620.6
Trade accounts payable	420,275.7	307,089.7
Provisions	123,474.3	82,428.0
Accruals	0.0	0.0
other accounts payable	284,776.4	241,934.9
other current liabilities	408,250.8	324,362.9
Current liabilities	2,317,880.7	1,766,073.2
Shareh. equity, min. int. & liabilities	4,510,594.1	3,702,316.1
Profit and loss account		
Sales	4,867,452.5	4,935,229.9
Reduction of proceeds	164,964.0	197,389.3
Net sales	4,702,488.5	4,737,840.6
Other operating revenue	102,893.4	59,236.3
Operating revenue	4,805,381.9	4,797,076.9
Cost of goods sold	3,160,349.1	3,533,089.5
Gross profit	1,645,032.8	1,263,987.4
Other operating expenses	1,256,511.1	919,286.6
Operating result	388,521.7	344,700.8
Interest revenues	0.0	0.0
other financial revenues	75.0	-3,540.3
Financial income	75.0	-3,540.3
Interest expenses	142,733.9	71,717.4
other financial expenses	88,961.1	28,028.6
Financial expenses	231,695.0	99,746.0
Financial result	-231,620.0	-103,286.3
Result before extraordinary items	156,901.6	241,414.5

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SHIVA PHARMACHEM SA - 530442

PAGE NO. : 9

Extraordinary income	-10.4	-3,338.8
Extraordinary expenses	0.0	0.0
Extraordinary Result	-10.4	-3,338.8
Result before taxes	156,891.2	238,075.8
Taxes	1,597.6	82,400.7
Result before minority interests	155,293.7	155,675.1
minority interests	0.0	0.0
Result for the financial year	155,293.7	155,675.1
Cash flow		
Depreciation	279,061.0	191,954.9
Cash flow	434,354.6	347,630.0
Cash flow from operating activities	891,288.6	482,649.8
Investments in tangible fixed assets	555,390.7	819,963.1
Cash flow from investing activities	-673,278.9	-826,475.9
Cash flow from financing activities	60,961.2	514,693.0
Others	-1,289,586.1	-705,333.1
Change in liquidity	214,020.2	89,099.5
Liquidity at beginning of the year	-214,020.2	-89,099.5
Liquidity at end of the year	421,229.8	196,216.4
Notes		
Material costs	2,425,713.3	1,769,830.3
Cost of employees	320,724.1	186,110.6
Added value	899,410.2	687,858.6
Working Capital	1,305,631.1	1,065,148.6
Net Current Assets	171,396.3	147,201.4

FINANCIALS

Balance sheet publication:

- The subject company only discloses limited financial figures.
- The Key Figures for the year 2016 are not available.

LEGAL ACTIONS

No legal actions determined

An updated legal action check is only available against proof of interest. e.g. a copy of an enquiry letter, and order or invoice relating to the subject company.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SANCTIONS LIST

We did not find the company included on the various international sanctions lists, such as the OFAC (Office of Foreign Assets Control), the BIS (Bureau of Industry and Security), the European Union Restrictive measures (sanctions) list, the Export Control Organisation (ECO) of the UK, the Australian Department of Foreign Affairs and Trade.

PAYMENT EXPERIENCES

No payment history is available.

CREDIT INFORMATION

Financial Situation: The financial situation is considered to be in order.

Payment experiences: There are no objections regarding the payment of financial obligations.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 71.85
UK Pound	1	INR 95.15
Euro	1	INR 84.68
CHF	1	INR 75.37

Note: Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	PRA
Report Prepared by :	NIT

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)